Literature DB >> 9465153

Risk factors for type 1 reactions in leprosy.

P W Roche1, J Le Master, C R Butlin.   

Abstract

A cohort of new borderline leprosy patients seen over a 7-year period were examined retrospectively for risk of type 1 reactions (T1R) associated with 12 clinical and laboratory parameters. Logistic regression analysis was used to identify a strong link between facial patches and cutaneous T1R and enlarged ulnar nerves and neural T1R. Anti-phenolic glycolipid-I seropositivity, a positive bacterial index, and disease in more than two body areas were also identified as risk factors for T1R. These data indicate that there are important clinical data which can be used to predict an individual patient's risk of developing T1R.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9465153

Source DB:  PubMed          Journal:  Int J Lepr Other Mycobact Dis        ISSN: 0148-916X


  6 in total

1.  High levels of inflammatory cytokines are associated with poor clinical response to steroid treatment and recurrent episodes of type 1 reactions in leprosy.

Authors:  R Manandhar; N Shrestha; C R Butlin; P W Roche
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

2.  Leprosy patients with deformities at post-elimination stage: The Bangladesh experience.

Authors:  M R Mowla; D M Angkur; Z Hasan; M N Sultana; S Afrin; M S Akhter
Journal:  Skin Health Dis       Date:  2020-10-14

Review 3.  Understanding the type 1 reactional state for early diagnosis and treatment: a way to avoid disability in leprosy.

Authors:  José Augusto da Costa Nery; Fred Bernardes Filho; Juliana Quintanilha; Alice Miranda Machado; Soraya de Souza Chantre Oliveira; Anna Maria Sales
Journal:  An Bras Dermatol       Date:  2013 Sep-Oct       Impact factor: 1.896

4.  Longitudinal immune profiles in type 1 leprosy reactions in Bangladesh, Brazil, Ethiopia and Nepal.

Authors:  Saraswoti Khadge; Sayera Banu; Kidist Bobosha; Jolien J van der Ploeg-van Schip; Isabela M Goulart; Pratibha Thapa; Chhatra B Kunwar; Krista E van Meijgaarden; Susan J F van den Eeden; Louis Wilson; Senjuti Kabir; Hymonti Dey; Luiz R Goulart; Janaina Lobato; Washington Carvalho; Yonas Bekele; Kees L M C Franken; Abraham Aseffa; John S Spencer; Linda Oskam; Tom H M Otttenhoff; Deanna A Hagge; Annemieke Geluk
Journal:  BMC Infect Dis       Date:  2015-10-28       Impact factor: 3.090

5.  Multibacillary leprosy patients with high and persistent serum antibodies to leprosy IDRI diagnostic-1/LID-1: higher susceptibility to develop type 2 reactions.

Authors:  Danielle de Freitas Mizoguti; Emerith Mayra Hungria; Aline Araújo Freitas; Regiane Morillas Oliveira; Ludimila Paula Vaz Cardoso; Mauricio Barcelos Costa; Ana Lúcia Maroclo Sousa; Malcolm S Duthie; Mariane Martins Araújo Stefani
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-11       Impact factor: 2.743

6.  Whole blood RNA signatures in leprosy patients identify reversal reactions before clinical onset: a prospective, multicenter study.

Authors:  Maria Tió-Coma; Anouk van Hooij; Kidist Bobosha; Jolien J van der Ploeg-van Schip; Sayera Banu; Saraswoti Khadge; Pratibha Thapa; Chhatra B Kunwar; Isabela M Goulart; Yonas Bekele; Deanna A Hagge; Milton O Moraes; Rosane M B Teles; Roberta Olmo Pinheiro; Erik W van Zwet; Jelle J Goeman; Abraham Aseffa; Mariëlle C Haks; Tom H M Ottenhoff; Robert L Modlin; Annemieke Geluk
Journal:  Sci Rep       Date:  2019-11-29       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.